Table 2.
Correlation of patient survival with hepatocyte growth factor receptor (MET)‐immunostaining and MET‐amplified tumour areas
| Final MET status | Group | Immunohistochemistry | Chromogenic in‐situ hybridization | Number of patients | Median survival ± SD (months) | 95% CI |
|---|---|---|---|---|---|---|
| Positive | A | MET‐IHC‐2+ and/or 3+ | MET amplified area ≥10% | 13 | 3.81 ± 1.71 | 0.47–7.16 |
| Positive | B | MET‐IHC‐2+ and/or 3+ | MET amplified area <10% | 12 | 4.27 ± 0.57 | 3.15–5.39 |
| Positive | C | MET‐IHC‐3+ | MET unamplified | 8 | 5.85 ± 6.27 | 5.43–6.27 |
| Negative | D | MET‐IHC‐2+ | MET unamplified | 22 | 18.76 ± 8.82 | 1.47–36.05 |
| Negative | E | MET‐IHC1+ or 0 | MET unamplified | 415 | 16.53 ± 1.45 | 13.69–19.37 |
MET, Hepatocyte growth factor receptor; IHC, Immunohistochemsitry; CISH, Chromogenic in‐situ hybridization; CI, Confidence interval; SD, Standard deviation.